drugset / Trial / NCT00624819
Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This protocol posting deals with objectives \& outcome measures of the extension phase up to 48-50 months post booster vaccination, to assess long-term antibody persistence in children at around 30, 42 and 66 months of age, who received previously 4 doses of pneumococcal conjugate vaccine. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = 00307554). This Protocol posting has been updated in order to comply with the FDA AA (Sep 2007).
Timeline
- Start
- 2008-03-03
- Primary completion
- 2008-06-02
- Completion
- 2008-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Havrix | Vaccine | — | — |
| Background | Infanrix hexa | Vaccine | — | — |
| Background | Prevnar 13 | Vaccine | — | — |
| Background | Synflorix | Vaccine | — | — |
| Background | Varilrix | Vaccine | — | — |